Abstract
Accurate therapeutic prognostication continues to elude the head and neck oncologist, hindering de-intensification efforts and maximizing adjuvant therapy related toxicity. We examined three biomarkers: mutant allele tumor heterogeneity (MATH, a quantitative measure of intra-tumor genetic heterogeneity), and HPV and Estrogen Receptor alpha (ER-alpha) status in patients from the Cancer Genome Atlas (TCGA) treated with chemoradiotherapy (CRT). We hypothesized that this combination of biomarkers would prognosticate treatment outcome better than HPV status alone, allowing improved identification of patients at low and high risk of treatment failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
